blood clotting disorders

FDA Approves Emicizumab-kxwh for Hemophilia A
FDA Approves Emicizumab-kxwh for Hemophilia AEmicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.
Treatment investigated to prevent blood-clotting disordersA new subcutaneous therapy could offer a promising solution to a bleeding disorder in both children and adults.